# AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study

> **NCT03100123** · EARLY_PHASE1 · TERMINATED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 1 (actual)

## Conditions studied

- Antiphospholipid Syndrome in Pregnancy
- Pregnancy Loss

## Interventions

- **DRUG:** Aspirin 81 mg
- **DRUG:** Low-molecular-weight heparin

## Key facts

- **NCT ID:** NCT03100123
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-06
- **Primary completion:** 2019-10-07
- **Final completion:** 2019-10-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Pilot deemed not feasible by Steering Committee due to recruitment rate.
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03100123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03100123, "AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03100123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*